TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15631714

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of Triptorelin (3.75 mg) at 6 weeks intervals in group A
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of Triptorelin (3.75 mg) at 4 weeks intervals in group B
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both treatment regimes (SC and IM)
Number of subjects: 46
Study: 11705848

Group type: EXPERIMENTAL
Intervention: 4-hydroxyphenylretinamide (4-HPR) at 200 mg/day for 6 months (with a 3-day/month drug holiday)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9146313

Group type: COMPARATOR
Intervention: Normothermic retrograde blood cardioplegia (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 minutes of global ischemia followed by reperfusion with antegrade and retrograde blood cardioplegia (preconditioned group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (control and preconditioned)
Number of subjects: 30
Study: 7952601

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta 2-agonists
Number of subjects: 0
Study: 30368332

Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention (YE) for 12 weeks
Number of subjects: 15
Study: 29231563

Group type: EXPERIMENTAL
Intervention: Acupuncture at Baihui(GV 20) and Shenting(GV 24) combined with basic treatment and regular rehabilitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Basic treatment and regular rehabilitation
Number of subjects: 50
Study: 24158311

Group type: EXPERIMENTAL
Intervention: Stimulating Healthy participation And Relapse Prevention at work intervention (problem-solving intervention)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study: 22420538

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) extubation protocol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard medical treatment (SMT) including NIV if indicated
Number of subjects: 75
Study: 20435231

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/d
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 19863407

Group type: EXPERIMENTAL
Intervention: Toremifene (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16513450

Group type: EXPERIMENTAL
Intervention: CGRP8‐37 (333 ng.min(‐1).dL(‐1) forearm)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CGRP (10 ng.min(‐1).dL(‐1) forearm) with CGRP8‐37 (300, 600, or 1200 ng.min(‐1).dL(‐1) forearm)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CGRP8‐37
Number of subjects: 21
Study: 14682406

Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone (QVAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFC-beclomethasone (Vanceril)
Number of subjects: 0
Study: 10594430

Group type: EXPERIMENTAL
Intervention: Blood conservation system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional system
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Haemofiltration (both groups)
Number of subjects: 100
Study: 9496205

Group type: EXPERIMENTAL
Intervention: Fentanyl 200 micrograms and midazolam 0.2 mg kg‐1 (fentanyl group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo and midazolam 0.2 mg kg‐1 (placebo group, n = 15)
Number of subjects: 30
Study: 8365971

Group type: EXPERIMENTAL
Intervention: BCAA (leucine + isoleucine + valine, 77 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (dextrose, 77 mg/kg)
Number of subjects: 7
Study: 2939571

Group type: EXPERIMENTAL
Intervention: Back school intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Exercise-only regimen
Number of subjects: 78
Study: 30157844

Group type: EXPERIMENTAL
Intervention: Independent medical evaluation (IME)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Second opinion from an experienced GP colleague
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Selection of particularly challenging sick-listed patients for IME
Number of subjects: 14
Study: 25818103

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet, smoking cessation, and exercise) with oral and written information provided in a booklet for postoperative rehabilitation.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Regular oral instructions (Control group).
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet, smoking cessation, and exercise).
Number of subjects: 500
Study: 23864581

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy (more than 360 defined daily doses)
Number of subjects: 65754

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy (more than 1080 defined daily doses)
Number of subjects: 65754

Group type: EXPERIMENTAL
Intervention: Metformin in combination with other antidiabetic drugs
Number of subjects: 65754

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 65754

Group type: COMPARATOR
Intervention: Type 2 diabetes patients not on diabetes drugs
Number of subjects: 65754

Group type: COMPARATOR
Intervention: Antidiabetic drugs other than metformin
Number of subjects: 65754
Study: 22735495

Group type: EXPERIMENTAL
Intervention: Wood stove replacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Air filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham air filter placebo
Number of subjects: 0
Study: 19633952

Group type: EXPERIMENTAL
Intervention: Brief 2-hour discussion group for parents
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 46
Study: 18519824

Group type: EXPERIMENTAL
Intervention: Imaginal and in vivo exposure (n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list control group (n = 30)
Number of subjects: 90
Study: 16061501

Group type: EXPERIMENTAL
Intervention: Pre-hospital combination-fibrinolysis with facilitated PCI
Number of subjects: 164

Group type: COMPARATOR
Intervention: Pre-hospital combination-fibrinolysis
Number of subjects: 164
Study: 12769413

Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine (EBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 10365640

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg/d for 1 week
Number of subjects: 29
Study: 9816035

Group type: EXPERIMENTAL
Intervention: Amonafide at 300 mg/m2/day i.v. for 5 days, repeated at 21-day intervals for a maximum of four cycles.
Number of subjects: 0
Study: 1675367

Group type: EXPERIMENTAL
Intervention: Chorion villus sampling
Number of subjects: 3248

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 3248
Study: 7003611

Group type: EXPERIMENTAL
Intervention: 2 mg DT gamma E (intra-muscular injections for 4 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (injections for 4 days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: DT gamma E
Number of subjects: 13
Study: 31159822

Group type: EXPERIMENTAL
Intervention: EMG-driven NMES-robotic support to the finger joints (hand group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: EMG-driven NMES-robotic support to the wrist-elbow joints (sleeve group, n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (hand and sleeve)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hand group
Number of subjects: 30
Study: 28242714

Group type: EXPERIMENTAL
Intervention: Time-averaged on-treatment SBP at 120 to 130 mm Hg (mean, 126.2 mm Hg)
Number of subjects: 17720

Group type: COMPARATOR
Intervention: Time-averaged on-treatment SBP at 130 to 135 mm Hg (mean, 132.6 mm Hg)
Number of subjects: 17720

Group type: COMPARATOR
Intervention: Time-averaged on-treatment SBP at 135 to 140 mm Hg (mean, 137.5 mm Hg)
Number of subjects: 17720

Group type: COMPARATOR
Intervention: Time-averaged on-treatment SBP <120 mm Hg (mean, 116.7 mm Hg)
Number of subjects: 17720
Study: 25968576

Group type: EXPERIMENTAL
Intervention: Femoral lipectomy (LIPO)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 29
Study: 22904126

Group type: EXPERIMENTAL
Intervention: Higher-intensity warm-up protocols performed near testing
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Wearing a light survival coat during warm-ups
Number of subjects: 6
Study: 21466926

Group type: EXPERIMENTAL
Intervention: Cocaine cues
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Subjective craving
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resting state correlation
Number of subjects: 14
Study: 18619811

Group type: EXPERIMENTAL
Intervention: Complex intervention comprising reviews of centers, training programmes, documents, and tailored feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex intervention
Number of subjects: 0
Study: 17969887

Group type: EXPERIMENTAL
Intervention: Gandou Decoction IV (GDIV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sodium dimercaptosulphonate (DMPS)
Number of subjects: 61
Study: 15273208

Group type: EXPERIMENTAL
Intervention: Community team-based primary data collectors
Number of subjects: 23

Group type: COMPARATOR
Intervention: Random audits
Number of subjects: 23
Study: 10665617

Group type: EXPERIMENTAL
Intervention: Testosterone administration (sublingual)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9309469

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8341998

Group type: EXPERIMENTAL
Intervention: Six-month therapy with daily Rifater for two months, followed by isoniazid and rifampicin for four months (n = 128)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Nine-month therapy with isoniazid and rifampicin daily for nine months, supplemented by ethambutol for the first two months (n = 133)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Initial drug resistance to isoniazid
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Subsequent multi-drug therapy
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Initial resistance to isoniazid and rifampicin
Number of subjects: 261
Study: 3525695

Group type: EXPERIMENTAL
Intervention: 1 X 10(6) IU of IFN‐alpha 2, 3 times per week for 12 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 3 X 10(6) IU of IFN‐alpha 2, 3 times per week for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 31113475

Group type: EXPERIMENTAL
Intervention: Culture-positive sepsis
Number of subjects: 2659

Group type: COMPARATOR
Intervention: Antibiotics at home
Number of subjects: 2659
Study: 28625592

Group type: EXPERIMENTAL
Intervention: Unstented TIPU
Number of subjects: 110

Group type: COMPARATOR
Intervention: Stented TIPU
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 110
Study: 25839406

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir (25mg/150mg/100mg once daily) and dasabuvir (250mg twice daily) + weight-based ribavirin for 12 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir + ribavirin
Number of subjects: 38
Study: 24067081

Group type: EXPERIMENTAL
Intervention: 0.9% saline (23 ml/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 3% saline (7 ml/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5% glucose (23 ml/kg)
Number of subjects: 23
Study: 21362274

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance combined with stimulating catheter (USNS group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stimulating catheter alone (NS group)
Number of subjects: 120
Study: 19616140

Group type: EXPERIMENTAL
Intervention: Individuals with OSA (39% of the sample)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Depression severity and insomnia severity
Number of subjects: 51
Study: 17182222

Group type: EXPERIMENTAL
Intervention: Monthly booster sessions for a further nine months
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine clinical care with no further group meetings
Number of subjects: 103
Study: 15492339

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 170
Study: 12235221

Group type: EXPERIMENTAL
Intervention: Two-drug combinations containing at least one new agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer targeted therapies
Number of subjects: 0
Study: 9555615

Group type: EXPERIMENTAL
Intervention: Cetirizine treatment for one week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment for one week
Number of subjects: 20
Study: 7480963

Group type: EXPERIMENTAL
Intervention: r-alpha-IFN-2a (3 MU thrice weekly for 12 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: r-alpha-IFN-2b (3 MU thrice weekly for 12 months)
Number of subjects: 35
Study: 2919963

Group type: EXPERIMENTAL
Intervention: Enteral lipids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no enteral lipids)
Number of subjects: 0
Study: 31735634

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg and 2.0 mg) administered monthly or on an as-needed basis (PRN)
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Dilated fundus examination (DFE) and fundus photography
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Spectral-domain OCT (SD-OCT)
Number of subjects: 1097
Study: 29265836

Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT) as guided self-help
Number of subjects: 242

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 242
Study: 28911091

Group type: EXPERIMENTAL
Intervention: S‐1/cisplatin
Number of subjects: 361

Group type: COMPARATOR
Intervention: 5‐FU/cisplatin
Number of subjects: 361
Study: 26258821

Group type: EXPERIMENTAL
Intervention: Vitamin group (1 g ascorbic acid and 600 IU D‐α‐tocopherol orally 60 min before the dive)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group (placebo treatment)
Number of subjects: 16
Study: 23885649

Group type: EXPERIMENTAL
Intervention: Early surgery (<48 h) for patients on antiplatelet therapy
Number of subjects: 175

Group type: COMPARATOR
Intervention: Delayed surgery (>5 days) for patients on antiplatelet therapy
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Early surgery (<48 h) for patients not on antiplatelet therapy
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Patients on antiplatelet therapy
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Overall mortality analysis
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Transfusion requirements
Number of subjects: 175
Study: 22160369

Group type: EXPERIMENTAL
Intervention: Endurance training program (3 times a week, cycling at 75% maximal heart rate) for 3 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 17
Study: 19394017

Group type: EXPERIMENTAL
Intervention: Falling Efficacy Scale (FES)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Activities-Specific Balance Confidence Scale (ABC)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Geriatric Fear of Falling Measurement (GFFM)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: FES vs. ABC
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: FES vs. GFFM
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: ABC vs. GFFM
Number of subjects: 168
Study: 16507182

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre during venepuncture
Number of subjects: 110

Group type: COMPARATOR
Intervention: No Valsalva manoeuvre during venepuncture
Number of subjects: 110
Study: 15093913

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy
Number of subjects: 46
Study: 11700577

Group type: EXPERIMENTAL
Intervention: Tafenoquine 400 mg for 3 days followed by placebo weekly
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg for 3 days followed by 200 mg per week
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tafenoquine 400 mg for 3 days followed by 400 mg per week
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo throughout
Number of subjects: 249
Study: 9142510

Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha monoclonal antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elderly with high NK activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elderly with low NK activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young individuals
Number of subjects: 0
Study: 7944932

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon gamma, 100 micrograms, administered subcutaneously once daily for 21 days (or until patient discharge if prior to 21 days)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 2895461

Group type: EXPERIMENTAL
Intervention: 1 mg loprazolam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31872398

Group type: EXPERIMENTAL
Intervention: Recreational swimming program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 28406803

Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging (MBB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sleep Education Control (SED)
Number of subjects: 60
Study: 26159167

Group type: EXPERIMENTAL
Intervention: Balloon dilatation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser myotomy
Number of subjects: 0
Study: 23420574

Group type: EXPERIMENTAL
Intervention: 400 ml beer (4.7% vol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 ml red wine (13.7% vol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 ml whisky (43.5% vol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matching volumes of control fluids
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcoholic beverages (beer, red wine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whisky and high proof ethanol solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcoholic beverages
Number of subjects: 12
Study: 17161050

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 12731402

Group type: EXPERIMENTAL
Intervention: Magnetotherapy (2.9 microT; frequency‐‐40 Hz; square wave; Magnetronic MF‐‐10 apparatus) applied for 20 min to the lumbar area, repeated 15 times
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Magnetostimulation (Viofor JPS system; M2P2 program; induction‐‐25‐80 microT; frequency‐‐200 Hz, complex saw‐like shape) applied for 12 min daily, repeated 15 times
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of magnetotherapy and magnetostimulation
Number of subjects: 26
Study: 10431577

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy followed by hematopoietic stem cell transplant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study: 7742127

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR imaging using high dose (0.3 mmol/kg b.w.) Gadodiamide injection
Number of subjects: 16

Group type: COMPARATOR
Intervention: Contrast-enhanced MR imaging using standard dose (0.1 mmol/kg b.w.) Gadodiamide injection
Number of subjects: 16

Group type: COMPARATOR
Intervention: Contrast-enhanced CT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-contrast-enhanced MR imaging
Number of subjects: 16
Study: 1952841

Group type: EXPERIMENTAL
Intervention: Rimantadine (10 days treatment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rimantadine (5 days treatment)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6452790

Group type: EXPERIMENTAL
Intervention: Zimelidine (selective serotonin‐uptake inhibitor)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desipramine (selective norepinephrine uptake inhibitor)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both Zimelidine and Desipramine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study: 29546525

Group type: EXPERIMENTAL
Intervention: Swallowing exercise education program (SEEP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Both groups (Experimental and Control)
Number of subjects: 76
Study: 27995517

Group type: EXPERIMENTAL
Intervention: 3 cm group
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8 cm group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25873255

Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI)
Number of subjects: 50
Study: 22959094

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 10
Study: 21982652

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5400
Study: 18494625

Group type: EXPERIMENTAL
Intervention: ORC/collagen matrix
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (hydrocolloid dressing)
Number of subjects: 27
Study: 15722807

Group type: EXPERIMENTAL
Intervention: Observer NRS during stretching procedure
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: NCCPC-PV during stretching procedure
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CFCS scores across time segments
Number of subjects: 19
Study: 12947063

Group type: EXPERIMENTAL
Intervention: ACNU plus VM26 (90 mg/m2 IV on day 1 and 60 mg/m2 IV on days 1 to 3)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: ACNU plus Ara‐C (90 mg/m2 IV on day 1 and 120 mg/m2 IV on days 1 to 3)
Number of subjects: 362
Study: 10674508

Group type: EXPERIMENTAL
Intervention: rapacuronium 1 mg x kg(‐1)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: rapacuronium 2 mg x kg(‐1)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: rapacuronium 3 mg x kg(‐1)
Number of subjects: 103

Group type: COMPARATOR
Intervention: mivacurium 0.2 mg x kg(‐1)
Number of subjects: 103
Study: 8554083

Group type: EXPERIMENTAL
Intervention: Low-dose levodopa and carbidopa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Higher, conventional dose of levodopa and carbidopa
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1899080

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg, releasing 6 to 7 mg in 12 hr)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14